Standard BioTools Inc. (LAB) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone, and welcome to Standard BioTools' fourth quarter and full year 2024 financial results conference call. As a reminder, this conference is being recorded. It's now my pleasure to introduce your host, John Graziano from Investor Relations. Please go ahead. Thank you, operator, and good afternoon, everyone. Welcome to Standard BioTools' fourth quarter and full year 2024 earnings conference call. Leading the call today is Michael Eggholm, President and Chief Executive Officer, and Alex Kim, Chief Financial Officer. At the close of market today, Standard BioTools released its financial results for the quarter ended in year December 31st, 2024. During the call, we will review our results and provide an update on our financial and operational performance, 2025 outlook, market trends, and strategic initiatives. During the call, we'll make forward-looking statements about events and circumstances that have not yet occurred, including plans and projections for our business, our outlook for 2025 and future financial results, market trends and opportunities, and our expectations related to the combined operations with Somalogic, including potential synergies and our business outlook for the combined company. These statements are subject to substantial risks and uncertainties, that may cause actual events or results to differ materially from current expectations. The forward-looking statements on this call are based on information currently available to us, and we disclaim any obligation to update these statements except as they may be required by law. During the call, we will also present some financial information on a non-GAAP basis. We believe these non-GAAP financial measures are useful in evaluating our core performance and as a baseline for assessing the...